Markets

Insider Trading

Hedge Funds

Retirement

Opinion

The City With the highest HIV/AIDS Rates in the US

We recently compiled a list of 20 Cities With the Highest HIV/AIDS Rates in the US and in this article, we will talk about the city with the highest HIV/AIDS rates in the US.

HIV Incidence and Prevalence in the United States

The government of the United States has set a goal to reduce the number of HIV infections by 75% by 2025 and 90% by 2030 as part of its Ending the HIV Epidemic in the US initiative. According to the Centers for Disease Control (CDC), there were approximately 32,100 estimated new infections in 2021 by transmission category in the US. Of these new infections 70% were reported among gay, bisexual, and male-to-male sexual contact, 22% were reported to be transmitted by heterosexual contact, and around 8% were transmitted among people who inject drugs. As per the Ending the HIV Epidemic Initiative, the government aims to curb the new infection number to 9,000 new infections by 2025, and to 3,000 by 2030.

In a regional analysis of the HIV incidence and prevalence within the United States, South America accounted for approximately 52% of the new HIV infections, followed by the Western and Mid-Western regions with 21% and 14% new infections during 2021. Northeast America accounted for the least new infections and reported only a 14% new infection rate during the same year. Analyzing the diagnosis trends among different races and ethnicities within America reveals that during 2021, 36% of African American gay or bisexual men were diagnosed with HIV infection, followed by Hispanic/Latino and white Americans with 33% and 25% diagnosis rates during 2021. Although the overall HIV diagnosis shows improvement as compared to 2017 figures, with HIV diagnosis among men and women going down by 15% and 11% respectively from 2017 to 2021. However, the government still needs to go a long way in reaching its 2025 target as according to the AtlasPlus data by CDC, around 37,601 people were diagnosed with HIV in 2022, up by 5.41% as compared to 2021 diagnosis figures.

An Overview of the Global HIV Drug Market

According to a report by Fortune Business Insights, the global HIV drug market was valued at $34.13 billion in 2023. The market is forecasted to grow at a compound annual growth rate of 6.2% to reach $58.24 billion by 2032. The viral infection is spreading around the world at a growing rate. According to the World Health Organization, an estimated 39.0 million people were living with the infection in 2022. However, on the bright side, the number of incidence of new HIV cases has reduced since 2010. As per the data, approximately 1.3 million people acquired HIV in 2022 as compared to 2.1 million people acquiring the virus in 2010. The increased awareness of the virus, prompt diagnosis, and demand for treatment medication are factors contributing to growth in the market.

Some of the leading pharmaceutical companies contributing to curbing and treating HIV infection include GSK plc (NYSE:GSK) and Merck & Co., Inc. (NYSE:MRK).

GSK plc (NYSE:GSK) is a leading pharmaceutical company based in the United Kingdom that researches and develops vaccines and other general medicines. The company through its subsidiaries operates in the United Kingdom, the United States, and internationally. On March 5 Reuters reported that GSK plc’s (NYSE:GSK) new HIV drug formula could support longer dosing intervals. The new formula can be potentially administered at least every 4 months as opposed to the previous requirement of 2-month dosing intervals. Moreover, the company has shifted its focus to long-acting treatments and prevention therapies.

Merck & Co., Inc. (NYSE:MRK) is another international healthcare company that operates through two segments; pharmaceuticals and animal health. On March 6, Merck & Co., Inc. (NYSE:MRK) along with Gilead Sciences, Inc. (NASDAQ:GILD) announced the results of a phase 2 clinical trial showing an oral once-weekly combination of the Regimen of Islatravir and Lenacapavir as a viable option to suppress the viral HIV infection. The combination was found to maintain a high rate (94.2%) of viral suppression rate. Gilead Sciences, Inc. (NASDAQ:GILD) is a leading innovator in developing treatment and conducting cure research for HIV.

A researcher at a microscope, inspecting cells to find the cure for BK virus.

Our Methodology

To compile the list of 20 cities with the highest HIV/AIDS Rates in the US, we used the US Center for Disease Control and Prevention’s Data Atlas for HIV, Viral Hepatitis, STD, and Tuberculosis Prevention. From CDC’s Data Atlas, we selected the HIV and AIDS prevalence indicators, next, we selected Metropolitan Statistical Area (MSA) as our geography for the dataset and the latest year for which the data was available, in this case, it was 2022. Lastly, we selected the demographics for our dataset, which were ages 13 and older, all races/ethnicities, both sexes, and all transmission categories. With this, we had HIV and AIDS prevalence data of all major MSAs with a population of at least 500,000.

For this title we wanted to rank cities that had high rates of both HIV and AIDS, therefore, we averaged the rate per 100,000 of HIV and AIDS to rank the MSA’s.

Please note that the list contains major Metropolitan Statistical Areas (MSA), where each MSA contains multiple cities. The list is ranked in ascending order of the average rate of HIV and AIDS per 100,000. We have included the names of cities included in each MSA, in the list descriptions.

At Insider Monkey we are obsessed with the stocks that hedge funds pile into. The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 275% since May 2014, beating its benchmark by 150 percentage points (see more details here).

The City With the highest HIV/AIDS Rates in the US

1. Fort Lauderdale-Pompano Beach-Sunrise, Florida

Average Rate of HIV and AIDS per 100,000: 929.3%

AIDS Rate per 100,000: 614%

HIV Rate per 100,000: 1244.6%

HIV Cases: 20,733

AIDS Cases: 10,228

The Fort Lauderdale-Pompano Beach-Sunrise Metropolitan Statistical Area in the state of Florida ranks as the city with the highest HIV/AIDS rates in the US. The area consists of Fort Lauderdale, Pompano Beach, and Sunrise cities which are located close to each other. The area had a combined average rate of HIV and AIDS prevalence of 929.3% per 100,000 people in 2022.

In addition, there were approximately 20,733 HIV cases and 10,228 AIDS cases in the area in 2022. All three major cities in the metro area are famous for their beaches and nightlife.

To learn about other cities with the highest rates of HIV/AIDS in the United States, you can checkout our detailed report on the 20 Cities with the Highest HIV/AIDS Rates in the US.

At Insider Monkey, we delve into a variety of topics, however, our expertise lies in identifying the top-performing stocks. Currently, Artificial Intelligence (AI) technology stands out as one of the most promising fields. If you are looking for an AI stock that is more promising than NVDA but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.

READ NEXT: 15 Biggest Asian Car Companies by Sales and 20 Countries With Highest Rates Of AIDS.

Disclosure: None. This article is originally published on Insider Monkey.

AI Fire Sale: Insider Monkey’s #1 AI Stock Pick Is On A Steep Discount

Artificial intelligence is the greatest investment opportunity of our lifetime. The time to invest in groundbreaking AI is now, and this stock is a steal!

The whispers are turning into roars.

Artificial intelligence isn’t science fiction anymore.

It’s the revolution reshaping every industry on the planet.

From driverless cars to medical breakthroughs, AI is on the cusp of a global explosion, and savvy investors stand to reap the rewards.

Here’s why this is the prime moment to jump on the AI bandwagon:

Exponential Growth on the Horizon: Forget linear growth – AI is poised for a hockey stick trajectory.

Imagine every sector, from healthcare to finance, infused with superhuman intelligence.

We’re talking disease prediction, hyper-personalized marketing, and automated logistics that streamline everything.

This isn’t a maybe – it’s an inevitability.

Early investors will be the ones positioned to ride the wave of this technological tsunami.

Ground Floor Opportunity: Remember the early days of the internet?

Those who saw the potential of tech giants back then are sitting pretty today.

AI is at a similar inflection point.

We’re not talking about established players – we’re talking about nimble startups with groundbreaking ideas and the potential to become the next Google or Amazon.

This is your chance to get in before the rockets take off!

Disruption is the New Name of the Game: Let’s face it, complacency breeds stagnation.

AI is the ultimate disruptor, and it’s shaking the foundations of traditional industries.

The companies that embrace AI will thrive, while the dinosaurs clinging to outdated methods will be left in the dust.

As an investor, you want to be on the side of the winners, and AI is the winning ticket.

The Talent Pool is Overflowing: The world’s brightest minds are flocking to AI.

From computer scientists to mathematicians, the next generation of innovators is pouring its energy into this field.

This influx of talent guarantees a constant stream of groundbreaking ideas and rapid advancements.

By investing in AI, you’re essentially backing the future.

The future is powered by artificial intelligence, and the time to invest is NOW.

Don’t be a spectator in this technological revolution.

Dive into the AI gold rush and watch your portfolio soar alongside the brightest minds of our generation.

This isn’t just about making money – it’s about being part of the future.

So, buckle up and get ready for the ride of your investment life!

Act Now and Unlock a Potential 10,000% Return: This AI Stock is a Diamond in the Rough (But Our Help is Key!)

The AI revolution is upon us, and savvy investors stand to make a fortune.

But with so many choices, how do you find the hidden gem – the company poised for explosive growth?

That’s where our expertise comes in.

We’ve got the answer, but there’s a twist…

Imagine an AI company so groundbreaking, so far ahead of the curve, that even if its stock price quadrupled today, it would still be considered ridiculously cheap.

That’s the potential you’re looking at. This isn’t just about a decent return – we’re talking about a 10,000% gain over the next decade!

Our research team has identified a hidden gem – an AI company with cutting-edge technology, massive potential, and a current stock price that screams opportunity.

This company boasts the most advanced technology in the AI sector, putting them leagues ahead of competitors.

It’s like having a race car on a go-kart track.

They have a strong possibility of cornering entire markets, becoming the undisputed leader in their field.

Here’s the catch (it’s a good one): To uncover this sleeping giant, you’ll need our exclusive intel.

We want to make sure none of our valued readers miss out on this groundbreaking opportunity!

That’s why we’re slashing the price of our Premium Readership Newsletter by a whopping 70%.

For a ridiculously low price of just $29, you can unlock a year’s worth of in-depth investment research and exclusive insights – that’s less than a single restaurant meal!

Here’s why this is a deal you can’t afford to pass up:

  • The Name of the Game-Changing AI Stock: Our in-depth report dives deep into our #1 AI stock’s groundbreaking technology and massive growth potential.
  • One free upcoming issue of our 70+ page Quarterly Newsletter: A value of $149
  • Ad-Free Browsing: Enjoy a year of investment research free from distracting banner and pop-up ads, allowing you to focus on uncovering the next big opportunity.
  • Lifetime Money-Back Guarantee:  If you’re not absolutely satisfied with our service, we’ll provide a full refund ANYTIME, no questions asked.

 

Space is Limited! Only 1000 spots are available for this exclusive offer. Don’t let this chance slip away – subscribe to our Premium Readership Newsletter today and unlock the potential for a life-changing investment.

Here’s what to do next:

  1. Head over to our website and subscribe to our Premium Readership Newsletter for just $29.
  2. Enjoy a year of ad-free browsing, exclusive access to our in-depth report on the revolutionary AI company, and the upcoming issues of our Premium Readership Newsletter over the next 12 months.
  3. Sit back, relax, and know that you’re backed by our ironclad lifetime money-back guarantee.

Don’t miss out on this incredible opportunity! Subscribe now and take control of your AI investment future!

A New Dawn is Coming to U.S. Stocks

I work for one of the largest independent financial publishers in the world – representing over 1 million people in 148 countries.

We’re independently funding today’s broadcast to address something on the mind of every investor in America right now…

Should I put my money in Artificial Intelligence?

Here to answer that for us… and give away his No. 1 free AI recommendation… is 50-year Wall Street titan, Marc Chaikin.

Marc’s been a trader, stockbroker, and analyst. He was the head of the options department at a major brokerage firm and is a sought-after expert for CNBC, Fox Business, Barron’s, and Yahoo! Finance…

But what Marc’s most known for is his award-winning stock-rating system. Which determines whether a stock could shoot sky-high in the next three to six months… or come crashing down.

That’s why Marc’s work appears in every Bloomberg and Reuters terminal on the planet…

And is still used by hundreds of banks, hedge funds, and brokerages to track the billions of dollars flowing in and out of stocks each day.

He’s used this system to survive nine bear markets… create three new indices for the Nasdaq… and even predict the brutal bear market of 2022, 90 days in advance.

Click to continue reading…